Child’s Death Leads Beijing Health Officials To Suspend Use Of Sinovac’s Hepatitis A Vaccine
This article was originally published in PharmAsia News
Executive SummarySHANGHAI - District Health Services Bureau officials in Beijing have suspended the use of one batch of Sinovac's inactivated hepatitis A vaccine, Healive, while investigating a possible adverse drug reaction and death of a two-year-old girl who was administered the vaccine
You may also be interested in...
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).